Evaluation of CYP2D6 and efficacy of tamoxifen and raloxifene in women treated for breast cancer chemoprevention: Results from the NSABP P1 and P2 clinical trials

Clinical Cancer Research

Volumn 17, Issue 21, 2011, Pages 6944-6951

  Goetz, Matthew P ^a,b   Schaid, Daniel J ^a   Wickerham, D Lawrence ^c,d   Safgren, Stephanie ^b   Mushiroda, Taisei ^h   Kubo, Michiaki ^h   Batzler, Anthony ^a   Costantino, Joseph P ^e   Vogel, Victor G ^f,i   Paik, Soonmyung ^d   Carlson, Erin E ^a   Flockhart, David A ^g   Wolmark, Norman ^c   Nakamura, Yusuke ^h   Weinshilboum, Richard M ^b   Ingle, James N ^a   Ames, Matthew M ^b  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c ALLEGHENY GENERAL HOSPITAL   (United States)

^d NSABP Foundation Inc   (United States)

^e UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^f UNIVERSITY OF PITTSBURGH   (United States)

^g INDIANA UNIVERSITY   (United States)

^h RIKEN   (Japan)

ⁱ GEISINGER HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6; DNA; ENDOXIFEN; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER INVASION; CASE CONTROL STUDY; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME METABOLISM; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PRIMARY PREVENTION; PRIORITY JOURNAL;

AGED; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CYTOCHROME P-450 CYP2D6; FEMALE; HUMANS; MIDDLE AGED; POSTMENOPAUSE; RALOXIFENE; TAMOXIFEN;

EID: 80455168584     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-0860     Document Type: Article

References (38)

1. Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005;97:1652-62. (Pubitemid 41672231)
2. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-88. (Pubitemid 28439961)
3. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al. Effects of tamoxifen vs. raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295:2727-41.
4. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer. Cancer Prev Res 2010;3:696-706.
5. Johnson MD, Zuo H, Lee KH, Trebley JP, Rae JM, Weatherman RV, et al. Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat 2004;85:151-9. (Pubitemid 38987269)
6. Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P, et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 2003;95:1758-64. (Pubitemid 38008898)
7. Desta Z, Ward BA, Soukhova NV, Flockhart DA. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 2004;310:1062-75. (Pubitemid 39108928)
8. Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH, et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005;97:30-9.
9. Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW, et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 2005;23:9312-8.
10. Schroth W, Goetz MP, Hamann U, Fasching PA, Schmidt M, Winter S, et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 2009;302:1429-36.
11. Bijl MJ, van Schaik RH, Lammers LA, Hofman A, Vulto AG, van Gelder T, et al. The CYP2D6*4 polymorphismaffects breast cancer survival in tamoxifen users. Breast Cancer Res Treat 2009;118:125-30.
12. Kelly CM, Juurlink DN, Gomes T, Duong-Hua M, Pritchard KI, Austin PC, et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ 2010;340:c693.
13. Kiyotani K, Mushiroda T, Imamura CK, Hosono N, Tsunoda T, Kubo M, et al. Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J Clin Oncol 2010;28:1287-93.
14. Lammers LA, Mathijssen RH, van Gelder T, Bijl MJ, de Graan AJ, Seynaeve C, et al. The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancer. Br J Cancer 2010;103:765-71.
15. Lim HS, Ju Lee H, Seok Lee K, Sook Lee E, Jang IJ, Ro J. Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer. J Clin Oncol 2007;25:3837-45. (Pubitemid 47477258)
16. Newman WG, Hadfield KD, Latif A, Roberts SA, Shenton A, McHague C, et al. Impaired tamoxifen metabolism reduces survival in familial breast cancer patients. Clin Cancer Res 2008;14:5913-8.
17. Serrano D, Lazzeroni M, Zambon CF, Macis D, Maisonneuve P, Johansson H, et al. Efficacy of tamoxifen based on cytochrome P450 2D6, CYP2C19 and SULT1A1 genotype in the Italian Tamoxifen Prevention Trial. Pharmacogenomics J 2011;11:100-7.
18. Dezentje VO, van Blijderveen NJ, Gelderblom H, Putter H, van Herk- Sukel MP, Casparie MK, et al. Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in earlystage breast cancer. J Clin Oncol 2010;28:2423-9.
19. Goetz MP, Berry DA, Klein TE. International Tamoxifen Pharmacogenomics Consortium. Adjuvant tamoxifen treatment outcome according to cytochrome P450 2D6 (CYP2D6) phenotype in early stage breast cancer: findings from the international tamoxifen pharmacogenomics consortium. Cancer Res 2009;492-3s.
20. Lash TL, Cronin-Fenton D, Ahern TP, Rosenberg CL, Lunetta KL, Silliman RA, et al. Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen. Acta Oncol 2010;49:305-12.
21. Nowell SA, Ahn J, Rae JM, Scheys JO, Trovato A, Sweeney C, et al. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res Treat 2005;91:249-58. (Pubitemid 40903087)
22. Okishiro M, Taguchi T, Jin Kim S, Shimazu K, Tamaki Y, Noguchi S. Genetic polymorphisms of CYP2D6*10 and CYP2C19*2,*3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen. Cancer 2009;115:952-61.
23. Ramon YCT, Altes A, Pare L, Del Rio E, Alonso C, Barnadas A, et al. Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment. Breast Cancer Res Treat 2010;119:33-8.
24. Siegelmann-Danieli N, Kurnik D, Lomnicky Y, Vesterman-Landes J, Katzir I, Bialik M, et al. Potent CYP2D6 inhibiting drugs do not increase relapse rate in early breast cancer patients treated with adjuvant tamoxifen. Breast Cancer Res Treat 2011;125:505-10.
25. Gnant M, Mlineritsch B, Stoeger H, Luscin-Ebengreuth G, Poestlberger S, Dubsky PC, et al. Mature results from ABCSG-12: adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zolendronic acid, in premenopausal women with endocrine-responsive early breast cancer (Abstract 533). J Clin Oncol 2010;28.
26. Wegman P, Elingarami S, Carstensen J, Stal O, Nordenskjold B, Wingren S. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res 2007;9:R7.
27. Wegman P, Vainikka L, Stal O, Nordenskjold B, Skoog L, Rutqvist LE, et al. Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res 2005;7: R284-90.
28. Dunn BK, Greene MH, Kelley JM, Costantino JP, Clifford RJ, Hu Y, et al. Novel pathway analysis of genomic polymorphism-cancer risk interaction in the breast cancer prevention trial. Int J Mol Epidemiol Genect 2010;1:332-49.
29. Borges S, Desta Z, Jin Y, Faouzi A, Robarge JD, Philips S, et al. Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients. J Clin Pharmacol 2010;50:450-8.
30. Dahabreh I, Terasawa T, Castaldi P, Trikalinos TA. CYP2D6 testing to predict response to tamoxifen in women with breast cancer: Pharmacogenomic PLoS Curr 2010;2. pii: RRN1176.
31. Leyland-Jones B, Regan MM, Bouzyk M, Kammler R, Tang W, Pagani O, et al. Outcome according to CYP2D6 genotype among postmenopausal women with endocrine-responsive early invasive breast cancer randomized in the big 1-98 trial [s1-8]. SABC 2010;.
32. Rae JM, Drury S, Hayes DF, Stearns V, Thibert JN, Haynes BP, et al. Lack of correlation between gene variants in tamoxifen metabolizing enymes with primary endpoints in the ATAC trial [Abstract S1-7]. Cancer Res 2009; 69(24 Suppl): Abstract nr 2011.
33. Goetz MP, Ames MM, Gnant M, Filpits M, Hanzel H, Jakesz R, et al. Pharmacogenetic (CYP2D6) and gene expression profiles (molecular grade index and HOXB13/IL17BR) for prediction of adjuvant endocrine therapy benefit in the ABCSG 8 trial Cancer Res2008;69(Suppl. abstract 57):76s.
34. Madlensky L, Natarajan L, Tchu MP. Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin Pharmacol Ther 2011:89:718-25.
35. Wu X, Hawse JR, Subramaniam M, Goetz MP, Ingle JN, Spelsberg TC. The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor {alpha} for degradation in breast cancer cells. Cancer Res 2009;69:1722-7.
36. Wu X, Subramaniam M, Grygo SB, Sun Z, Negron V, Lingle WL, et al. Estrogen receptor-beta sensitizes breast cancer cells to the antiestrogenic actions of endoxifen. Breast Cancer Res 2011;13:R27.
37. Zhao C, Lam EW, Sunters A, Enmark E, De Bella MT, Coombes RC, et al. Expression of estrogen receptor beta isoforms in normal breast epithelial cells and breast cancer: regulation by methylation. Oncogene 2003;22:7600-6. (Pubitemid 37464093)
38. Lu WJ, Desta Z, Flockhart DA. Tamoxifen metabolites as active inhibitors of aromatase in the treatment of breast cancer. Br Cancer Res Treat 2011. [Epub ahead of print].